Application No.: 10/622932

Docket No.: BPI-187

In the specification:

Please replace the second paragraph beginning at page 1, line 16 with the following paragraph:

This application is related to U.S. utility applications (Attorney Docket No. BPI-187) entitled "Treatment of TNFa Related Disorders Using TNFa Inhibitors," (Attorney Docket No. BPI 188) 10/623039 entitled "Treatment of Spondyloarthropathies Using TNFα Inhibitors," (Attorney Docket No. BPI 189) 10/623076 entitled "Treatment of Pulmonary Disorders Using TNFa Inhibitors," (Attorney Docket No. BPI-190) 10/623065 entitled "Treatment of Coronary Disorders Using TNFa Inhibitors," (Attorney Docket No. BPI 191) 10/622928 entitled "Treatment of Metabolic Disorders Using TNFa Inhibitors," (Attorney Docket No. BPI 192) 10/623075 entitled "Treatment of Anemia Using TNFα Inhibitors," (Attorney Docket No. BPI-193) 10/623035 entitled "Treatment of Pain Using TNFa Inhibitors," (Attorney Docket No. BPI-194) 10/622683 entitled "Treatment of Hepatic Disorders Using TNFα Inhibitors," (Attorney Docket No. BPI 195) 10/622205 entitled "Treatment of Skin and Nail Disorders Using TNFa Inhibitors," (Attorney Docket No. BPI-196) 10/622210 entitled "Treatment of Vasculitides Using TNFα Inhibitors," (Attorney Docket No. BPI 197) 10/623318 entitled "Treatment of TNF α -Related Disorders Using TNF α Inhibitors," and PCT application PCT/US2003/022566 (Attorney Docket No. BPI-187PC) entitled "Treatment of TNFα-Related Disorders," all of which are filed on even date herewith. The entire contents of each of these patents and patent applications are hereby incorporated herein by reference.